Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Dermatology
•
Systemic autoimmune diseases
Do you see a role for early, aggressive treatment for MCTD to prevent progression of disease, even though there has not been end-organ manifestations?
Related Questions
How would you approach management of a patient with rapidly progressive systemic sclerosis with worsening skin disease, myositis, arthritis, dysphagia and failure to thrive developing within 6 months?
How do you approach managing nausea and GI side effects when initiating methotrexate?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you go about switching from one DMARD to another In patients with dermatomyositis that remains active?
What treatments have you found most effective for cholestatic pruritus?
What is the likelihood of NXP2 false positivity from a dermatomyositis in a patient who is manifesting features of morphea?
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?
How would you interpret a positive single specific markers like SSA or SSB in setting of working up an connective tissue disease, especially when ANA is negative?
